UK – COVID-19 vaccine study focuses on young and immunosuppressed

Team at Imperial College London will expand MELODY study to include immunosuppressed young people

Immunosuppressed transplant recipients between the ages of 12 to 17-years-old have been added to the MELODY study population, which analyses how well additional doses of the COVID-19 vaccine protects immunosuppressed people.

The research project was first launched in December 2021 to evaluate third doses in adult patients and was supported by a coalition of funders including Kidney Research UK, The Medical Research Council, Blood Cancer UK, Vasculitis UK and the Cystic Fibrosis Trust…